Effect of saffron on neurological disability (modified Rankin scale) at hospitalization and one month post-discharge in patients with mild ischemic stroke

Document Type : Original Article

Authors

1 Assistant Professor of Neurosurgery School of Medicine Shahid Beheshti Hospital Qom University of Medical Sciences

2 Professor of Neurology Department of Neurology, School of Medicine Neuroscience Research Center Shahid Beheshti Hospital Qom University of Medical Sciences

3 Associate Professor of Epidemiology Department of Family and Community Medicine, School of Medicine Neuroscience Research Center Qom University of Medical Sciences

4 Neuroscience Research Center, Shahid Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran

5 Assistant Professor of Emergency Medicine Department of Emergency Medicine, School of Medicine Kerman University of Medical Sciences

6 Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran

Abstract
Background: Ischemic stroke is a major cause of neurological disability worldwide. Saffron (Crocus sativus L.) has demonstrated neuroprotective, antioxidant, and anti-inflammatory properties in experimental studies, but clinical evidence regarding its effect on functional recovery after stroke remains limited. This study primarily evaluated the effect of saffron supplementation on neurological recovery, and secondarily on functional disability, in patients with mild-to-moderate ischemic stroke.
Methods: In this randomized controlled open-label clinical trial, 74 patients with acute mild-to-moderate ischemic stroke were randomly assigned to either a saffron group (30 mg/day for 30 days plus standard treatment) or a control group receiving standard treatment alone.
Neurological and functional outcomes were assessed using the National Institutes of Health Stroke Scale (NIHSS) and the Modified Rankin Scale (mRS) at baseline, discharge, and one month post-discharge. Repeated-measures analysis of covariance (ANCOVA) was used to adjust for baseline laboratory differences.
Results: Baseline NIHSS and mRS scores were comparable between groups. The saffron group demonstrated significantly lower NIHSS scores at discharge (6.24 ± 2.11 vs. 7.70 ± 2.23; P = 0.005) and at one month (4.02 ± 2.45 vs. 6.81 ± 2.69; P < 0.001). Functional recovery was also superior in the saffron group, with lower one-month mRS scores (1.89 ± 0.80 vs. 3.00 ± 0.84; P < 0.001). Adjusted analyses confirmed significant time × group interactions for both NIHSS and mRS outcomes. No serious adverse events (SAEs) or mortality were observed.
Conclusion: Adjunctive saffron supplementation significantly improves neurological recovery (NIHSS) and promotes functional independence (mRS) in patients with mild-to-moderate ischemic stroke, without significant safety concerns.

Keywords

Subjects

1.     GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021; 20(10): 795-820.
2.     Feske SK. Ischemic Stroke. Am J Med 2021; 134(12): 1457-64.
3.     Kuriakose D, Xiao Z. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. Int J Mol Sci 2020; 21(20): 7609.
4.     Herpich F, Rincon F. Management of Acute Ischemic Stroke. Crit Care Med 2020; 48(11): 1654-63.
5.     Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007; 38(3): 1091-6.
6.     Freire MAM. Natural compounds in neuroprotection and nervous system regeneration: A narrative review. Regen Med Rep 2025; 3(3): 115-23.
7.     Singh D. Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research. CNS Neurol Disord Drug Targets 2015; 14(7): 880-902.
8.     Khazdair MR, Boskabady MH, Hosseini M, Rezaee R, A MT. The effects of Crocus sativus (saffron) and its constituents on nervous system: A review. Avicenna J Phytomed 2015; 5(5): 376-91.
9.     EFFECTS Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020; 19(8): 661-9.
10.  Elkind MSV, Veltkamp R, Montaner J, Johnston SC, Singhal AB, Becker K, et al. Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial. Neurology 2020; 95(8): e1091-e104.
11.  Asadollahi M, Nikdokht P, Hatef B, Sadr SS, Sahraei H, Assarzadegan F, et al. Protective properties of the aqueous extract of saffron (Crocus sativus L.) in ischemic stroke, randomized clinical trial. J Ethnopharmacol 2019; 238: 111833.
12.  Gudarzi S, Jafari M, Pirzad Jahromi G, Eshrati R, Asadollahi M, Nikdokht P. Evaluation of modulatory effects of saffron (Crocus sativus L.) aqueous extract on oxidative stress in ischemic stroke patients: a randomized clinical trial. Nutr Neurosci 2022; 25(6): 1137-46.
13.  Yousefi M, Sasannezhad P, Rakhshande H, Doosti H, Saki A, Baghestani Z, et al. Effect of Carthamus tinctorius L. (Safflower) on National Institute of Health Stroke Scale Scores of Ischemic Stroke Patients: A Pilot Clinical Trial. Trad Integr Med 2022; 7(2): 209-16.
14.  Ayati Z, Yang G, Ayati MH, Emami SA, Chang D. Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials. BMC Complement Med Ther 2020; 20(1): 333.
15.  Shahbaz K, Chang D, Zhou X, Low M, Seto SW, Li CG. Crocins for Ischemic Stroke: A Review of Current Evidence. Front Pharmacol 2022; 13: 825842.

Articles in Press, Accepted Manuscript
Available Online from 16 November 2026